N-3 Fatty Acids for Prevention of Cardiovascular Disease

Current Atherosclerosis Reports

Volumn 16, Issue 11, 2014, Pages

  Khawaja, Owais A ^a   Gaziano, John M ^b,c   Djoussé, Luc ^b,c  

^a ST VINCENT MERCY MEDICAL CENTER   (United States)

^b Division of SCI Research   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Arrhythmias; Cardiovascular disease; Heart failure; N 3 fatty acids

Indexed keywords

COLECALCIFEROL; DOCOSAHEXAENOIC ACID; FISH OIL; MARGARINE; OLIVE OIL; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; PLACEBO;

ANTIINFLAMMATORY ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CORONARY ARTERY ATHEROSCLEROSIS; DEFIBRILLATION; DIABETES MELLITUS; DIET SUPPLEMENTATION; DIET THERAPY; DRUG DOSE COMPARISON; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; EVIDENCE BASED MEDICINE; FATTY ACID BLOOD LEVEL; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; OUTCOME ASSESSMENT; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; THROMBOCYTE FUNCTION; TREATMENT DURATION; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); DIET; DRUG EFFECTS; METABOLISM; RISK FACTOR;

BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIET; FATTY ACIDS, OMEGA-3; HUMANS; RISK FACTORS;

EID: 84919920088     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-014-0450-0     Document Type: Review

References (44)

1. Go AS, Mozaffarian D, Roger VL, American Heart Association Statistics Committee and Stroke Statistics Subcommittee, et al. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–292.
2. Hu FB, Willett WC. Optimal diets for prevention of coronary heart disease. JAMA. 2002;288:2569–78.
3. Tanasescu M, Leitzmann MF, Rimm EB, et al. Exercise type and intensity in relation to coronary heart disease in men. JAMA. 2002;288:1994–2000.
4. Weisburger JH. Eat to live, not live to eat. Nutrition. 2000;16:767–73.
5. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med. 2000;343:16–22.
6. Krauss RM, Eckel RH, Howard B, et al. AHA dietary guidelines: revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation. 2000;102:2884–99.
7. Kris-Etherton PM, Harris WS, Appel LJ, American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106:2747–57.
8. ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, et al. N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309–18.
9. Risk and Prevention Study Collaborative Group, Roncaglioni MC, Tombesi M, Avanzini F, et al. N-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013;368:1800–8.
10. Kromhout D, Giltay EJ, Geleijnse JM, Alpha Omega Trial Group. N-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363:2015–6.
11. Wen YT, Dai JH, Gao Q. Effects of omega-3 fatty acid on major cardiovascular events and mortality in patients with coronary heart disease: a meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2014;24:470–5.
12. Casula M, Soranna D, Catapano AL, Corrao G. Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: a meta-analysis of randomized, placebo controlled trials [corrected]. Atheroscler Suppl. 2013;14:243–51.
13. Sekikawa A, Miura K, Lee S, ERA JUMP Study Group, et al. Long chain n-3 polyunsaturated fatty acids and incidence rate of coronary artery calcification in Japanese men in Japan and white men in the USA: population based prospective cohort study. Heart. 2014;100:569–73.
14. Urabe Y, Yamamoto H, Kitagawa T, et al. Association between serum levels of n-3 polyunsaturated fatty acids and coronary plaque detected by coronary computed tomography angiography in patients receiving statin therapy. Circ J. 2013;77:2578–85.
15. Maresta A, Balduccelli M, Varani E, ESPRIT Investigators, et al. Prevention of postcoronary angioplasty restenosis by omega-3 fatty acids: main results of the Esapent for Prevention of Restenosis ITalian Study (ESPRIT). Am Heart J. 2002;143:E5.
16. Bairati I, Roy L, Meyer F. Double-blind, randomized, controlled trial of fish oil supplements in prevention of recurrence of stenosis after coronary angioplasty. Circulation. 1992;85:950–6.
17. Reis GJ, Boucher TM, Sipperly ME, et al. Randomised trial of fish oil for prevention of restenosis after coronary angioplasty. Lancet. 1989;2:177–81.
18. Mozaffarian D, Lemaitre RN, King IB, et al. Circulating long-chain ω-3 fatty acids and incidence of congestive heart failure in older adults: the Cardiovascular Health Study: a cohort study. Ann Intern Med. 2011;155:166–70.
19. Wilk JB, Tsai MY, Hanson NQ, Gaziano JM, Djoussé L. Plasma and dietary omega-3 fatty acids, fish intake, and heart failure risk in the Physicians’ Health Study. Am J Clin Nutr. 2012;96:882–8.
20. Dijkstra SC, Brouwer IA, van Rooij FJ, et al. Intake of very long chain n-3 fatty acids from fish and the incidence of heart failure: the Rotterdam Study. Eur J Heart Fail. 2009;11:922–8.
21. Djoussé L, Akinkuolie AO, Wu JH, Ding EL, Gaziano JM. Fish consumption, omega-3 fatty acids and risk of heart failure: a meta-analysis. Clin Nutr. 2012;31:846–53.
22. Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1223–330.
23. Masson S, Marchioli R, Mozaffarian D, et al. Plasma n-3 polyunsaturated fatty acids in chronic heart failure in the GISSI-Heart Failure Trial: relation with fish intake, circulating biomarkers, and mortality. Am Heart J. 2013;165:208–15.
24. Kojuri J, Ostovan MA, Rezaian GR, et al. Effect of omega-3 on brain natriuretic peptide and echocardiographic findings in heart failure: double-blind placebo-controlled randomized trial. J Cardiovasc Dis Res. 2013;4:20–4.
25. Rauch B, Schiele R, Schneider S, OMEGA Study Group, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122:2152–9.
26. Jenkins DJ, Josse AR, Beyene J, et al. Fish-oil supplementation in patients with implantable cardioverter defibrillators: a meta-analysis. CMAJ. 2008;178:157–64.
27. Khoueiry G, Abi Rafeh N, Sullivan E, et al. Do omega-3 polyunsaturated fatty acids reduce risk of sudden cardiac death and ventricular arrhythmias? A meta-analysis of randomized trials. Heart Lung. 2013;42:251–6.
28. Lomivorotov VV, Efremov SM, Pokushalov EA, et al. Randomized trial of fish oil infusion to prevent atrial fibrillation after cardiac surgery: data from an implantable continuous cardiac monitor. J Cardiothorac Vasc Anesth. 2014.
29. Mariani J, Doval HC, Nul D, et al. N-3 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2013;2:e005033.
30. Khawaja O, Gaziano JM, Djoussé L. A meta-analysis of omega-3 fatty acids and incidence of atrial fibrillation. J Am Coll Nutr. 2012;31:4–13.
31. Maki KC, Orloff DG, Nicholls SJ, et al. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther. 2013;35:1400–11. e1401-1403.
32. Oliveira JM, Rondó PH. Omega-3 fatty acids and hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: systematic review and meta-analysis. HIV Clin Trials. 2011;12:268–74.
33. Hartweg J, Perera R, Montori V, et al. Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008; CD003205.
34. Ramel A, Martinez JA, Kiely M, Bandarra NM, Thorsdottir I. Effects of weight loss and seafood consumption on inflammation parameters in young, overweight and obese European men and women during 8 weeks of energy restriction. Eur J Clin Nutr. 2010;64:987–93.
35. Kelley DS, Siegel D, Fedor DM, Adkins Y, Mackey BE. DHA supplementation decreases serum C-reactive protein and other markers of inflammation in hypertriglyceridemic men. J Nutr. 2009;139:495–501.
36. Neff LM, Culiner J, Cunningham-Rundles S, et al. Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults. J Nutr. 2011;141:207–13.
37. Gao LG, Cao J, Mao QX, et al. Influence of omega-3 polyunsaturated fatty acid-supplementation on platelet aggregation in humans: a meta-analysis of randomized controlled trials. Atherosclerosis. 2013;226:328–34.
38. Wang Q, Liang X, Wang L, et al. Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis of randomized controlled trials. Atherosclerosis. 2012;221:536–43.
39. Tousoulis D, Plastiras A, Siasos G, et al. Omega-3 PUFAs improved endothelial function and arterial stiffness with a parallel antiinflammatory effect in adults with metabolic syndrome. Atherosclerosis. 2014;232:10–6.
40. Iketani T, Takazawa K, Yamashina A. Effect of eicosapentaenoic acid on central systolic blood pressure. Prostaglandins Leukot Essent Fat Acids. 2013;88:191–5.
41. Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens. 2002;20:1493–9.
42. Veljović M, Popadić A, Vukić Z, et al. Myocardial protection during elective coronary artery bypasses grafting by pretreatment with omega-3 polyunsaturated fatty acids. Vojnosanit Pregl. 2013;70(5):484–92.
43. Castillo RL, Arias C, Farías JG. Omega 3 chronic supplementation attenuates myocardial ischaemia-reperfusion injury through reinforcement of antioxidant defense system in rats. Cell Biochem Funct. 2014;32:274–81.
44. Khairallah RJ, Sparagna GC, Khanna N, et al. Dietary supplementation with docosahexaenoic acid, but not eicosapentaenoic acid, dramatically alters cardiac mitochondrial phospholipid fatty acid composition and prevents permeability transition. Biochim Biophys Acta. 2010;1797:1555–62.